Patent Application
20170049806
The present invention relates to a granular composition for oral suspension characterized by the presence of an insoluble resin and a silica gel.
It is known that insoluble resins, such as Sevelamer, Cholestyramine or Colesevelam, are extremely helpful in treating several pathologies such as hypercholesterolemia (acting as bile acid sequestrants) or hyperphosphataemia (acting as phosphate binding drug) in patients with chronic kidney diseases.
These insoluble resins are all characterized by:
These characteristics cause serious issues in formulating granular compositions for oral suspension to be filled in a container, such as sachets or cans.
In fact, due to these negative properties, the Health Authorities (such as the Food and Drug Administration) did not authorize to fill containers (sachets or cans) with said insoluble resins over the limits of ±5% of the target weight for each container.
Usually, in order to solve the difficulties related to the low flowability of the granular composition and to the poor uniformity content of the containers, the formulators are obliged to use special dosage equipments.
However, the use of special dosage equipments often do not solve these problems because of the poor wettability and floating on the surface of the liquid—thus remaining immiscible—of the granular composition, caused by the electrostatic charges of said granular composition.
Thus, granular compositions for oral administration comprising such insoluble resins in higher amount for each container and with better flowability and uniformity are needed.
Silica gels are usually used in several industrial applications, and particularly in pharmaceutical field, because of their considerable absorbing power, and their enormous surface area.
Surprisingly, it has been found that the granular compositions comprising insoluble resins, such as Sevelamer, Cholestyramine or Colesevelam, lose all the negative characteristics mentioned-above when a certain amount of silica gel, preferably highly porous silica gel having a mesoporous structure such as Syloid® XDP or Syloid® FP, is added to said granular compositions, thus allowing a better wettability of the insoluble granular composition, and the preparation of reliable dosage forms. In addition, if such silica gels are used in the compositions of the present invention an higher amount of insoluble resins for each container can be used.
The present invention refers to a granular composition for oral suspension characterized by the presence of an insoluble resin and a silica gel.
For the purpose of the present invention, the expression “porosity of a material” refers to the % ratio between the volume of the pores and the total volume of the considered material.
For the purpose of the present invention, the expression “highly porous material” refers to a material which has a porosity higher than 20%, preferably higher than 40%, even more preferably higher than 60%. In a preferred embodiment, the highly porous material has a porosity comprised in the range of 60-95%.
For the purpose of the present invention the expression “mesoporous material” refers to a material with a porous diameter size comprised in the range of 2-50 nm.
Silica gels (such as Syloid®), which are characterized by a high porosity and a mesoporous structure, are widely used within the pharmaceutical industry as excipients and processing aids.
The properties and the characteristics of such silica gels are known in the literature. They are referenced by FDA's as inactive ingredients and are specifically cited in numerous drug patents due to their unique morphology and properties that improve the handling, adsorption, and dissolution of many pharmaceuticals. In fact, the combined adsorption capacity, porosity, particle size, and greater internal surface area allow them to provide several benefits simultaneously that can help to minimize the number of excipients required, to expedite manufacturing, and to improve efficacy of the final dosage form.
Examples of commercial Syloid® to be used according to the present invention are Syloid® XDP-3050, Syloid® XDP-3150, and Syloid® FP.
Syloid® XDP usually refers to silica carriers consisting of an optimized mesoporous material, engineered for transforming liquids to free flowing solids, particularly oily actives and lipid-based systems. Generally speaking, such carriers lead to several advantages, such as transforming liquids to easy to handle solids, improving bioavailability of oily actives, increasing API loading in solid dosage forms; quick releasing of API.
Syloid® FP are usually used in the pharmaceutical applications as effective desiccants to increase the stability of moisture-sensitive APIs, as efficient conditioners for powder formulations used in suspensions, as capillary wetting agents for better release and disintegration.
The present invention refers to a granular composition for oral administration comprising a non soluble resin and a silica gel selected from the group consisting of: Syloid® FP and Syloid® XDP. More preferably, the silica gel is Syloid® XDP. Even more preferably, Syloid® XDP is Syloid® XDP-3050 or Syloid® XDP-3150. Syloid® XDP-3050 is preferred.
Preferably, the silica gel is Syloid® FP in the range of 0.1%-5% (w/w)
Preferably, the silica gel is Syloid® XDP in the range of 0.4%-1.0% (w/w).
Preferably, the insoluble resin of the granular composition of the present invention is selected from the group consisting of: Sevelamer carbonate, Sevelamer hydrochloride, Cholestyramine and Colesevelam hydrochloride. Sevelamer carbonate is preferred.
In a preferred embodiment, the granular composition of the present invention, further comprises a flavour, when the insoluble resin is Sevelamer carbonate.
More preferably, the flavour is selected from the group consisting of: citrus flavour, berry flavour, peach flavour, apricot flavour, mint flavour, anise flavour, grape flavour, cherry flavour and a mixture thereof. Citrus flavour is preferred.
Preferably, the granular composition of the present invention further comprises an artificial sweetener when citrus flavor is used. Preferably the artificial sweetener is aspartame.
Surprisingly, it has been found that the silica gel disclosed in the present invention advantageously reduces the electrostatic charges of the granular composition; therefore, the wettability of the insoluble granular composition is increased, thus allowing the preparation of reliable dosage forms. In fact, by using the silica gel disclosed herein the dispersion in a liquid, when orally administered, is facilitated.
In addition, another advantage of the present invention is that the granular composition here disclosed can be easily filled in sachets using a traditional dosing machine filled by gravity, and not the special equipments usually used and known in the state of the art, thus producing sachets with a Variation Coefficient (CV) of no more than (NMT) 3% or filled in cans with CV of NMT 3%.
Moreover, when bulk in water, the granular composition of the present invention rapidly forms a jelly suspension, thus advantageously allowing the correct administration of the medicament.
The following examples better illustrate the present invention without limiting it.
Please note that, for the purposes of the present invention, the meaning of the following acronyms is reported below:
The following compositions A-S have been prepared by pouring the ingredients listed in the Tables below:
Citrus
Citrus Flavour
Citrus Flavour
The resulting mix were blended for 10 minutes and were collected in a container.
The mix were then characterized from physical point of view.
The mix was then filled in a Marchesini RC 600 filling machine equipped with a dosing device filled by gravity, and the product was filled in Aluminium-Aluminium sachets in reason of 9.0 g each, or alternatively in a composite can, containing 239.4 or 378 g of granular and dispensed with a spoon corresponding to 5.7 g or 9.0 g of mixture.
A sachet comprising formula selected among A-S was then suspended in 60 ml of tap water; the characteristics of the derived suspensions are reported in the Table below
From the data reported above, it is thus clear that both Syloid® XDP-3050 and Syloid® XDP-3150 are suitable for the present invention; Syloid® XDP-3050 is preferred.
By making a comparison between the suspensions comprising the following compositions:
Moreover, a significant increase of Syloid® XDP-3050 (around 5%) in the composition, did not improve the physical parameters, but increased the sedimentation speed (see the compositions A and E, G and M, and N and R, where the appearance of the suspension after 1 minute of compositions A, G and N is “Homogeneous, cloudy”, whereas for compositions E, M and R is “Totally sediment” or “Product floating on the surface of the water”).
